Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 32341751
Ballester B, Milara J, Cortijo J (2020) Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation. Oncotarget 32341751
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T1224-p - MUC1 (human)
Modsite: RyVPPsstDRsPyEK SwissProt Entrez-Gene
Orthologous residues
MUC1 (human): T1224‑p, MUC1 iso2 (human): T1233‑p, MUC1 iso6 (human): T199‑p, MUC1 iso10 (human): T172‑p, MUC1 (mouse): T599‑p, MUC1 (rat): T43‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma
Relevant cell lines - cell types - tissues:  A549 (pulmonary), MRC5 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
pirfenidone TGF-beta inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  intracellular localization
Effect of modification (process):  cell growth, induced, transcription, induced
Comments:  induces nuclear translocation of the p-SMAD3/MUC1-CT/act-ß-catenin complex

Y1229-p - MUC1 (human)
Modsite: sstDRsPyEKVsAGN SwissProt Entrez-Gene
Orthologous residues
MUC1 (human): Y1229‑p, MUC1 iso2 (human): Y1238‑p, MUC1 iso6 (human): Y204‑p, MUC1 iso10 (human): Y177‑p, MUC1 (mouse): Y604‑p, MUC1 (rat): Y48‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma
Relevant cell lines - cell types - tissues:  A549 (pulmonary), MRC5 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TGF-beta increase
pirfenidone TGF-beta inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  intracellular localization
Effect of modification (process):  cell growth, induced, transcription, induced
Comments:  induces nuclear translocation of the p-SMAD3/MUC1-CT/act-ß-catenin complex